FDMT vs REGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FDMT and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FDMT and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, and known as 4DMT) is an Emeryville, California biotech founded in 2013 that engineers adeno-associated virus (AAV) vectors through a directed-evolution platform the company calls Therapeutic Vector Evolution. Its lead candidate, 4D-150, pairs the proprietary R100 vector with a transgene encoding aflibercept plus an RNA interference approach against VEGF-C, delivered by a single in-office intravitreal injection. The goal is to replace repeated monthly or bimonthly anti-VEGF eye injections with one durable treatment. Two Phase 3 wet AMD trials are fully enrolled: 4FRONT-1 randomized 523 patients with topline data guided to Q2 2027, and 4FRONT-2 finished enrollment in June 2026 with more than 500 patients and topline guided to H2 2027. A Phase 3 in diabetic macular edema was slated to start in Q3 2026. Behind the retina franchise sit 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis lung disease, and 4D-725 for alpha-1-antitrypsin deficiency, all of which the company says it is advancing mainly through outside funding rather than its own balance sheet.

Full FDMT guide

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.

Full REGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• FDMT drivers: Two fully enrolled Phase 3 wet AMD trials; Durability data that defines the commercial pitch.
• REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Everything concentrates in one molecule and two readouts, so a miss or an ambiguous result in 4FRONT-1 or 4FRONT-2 would remove most of the reason to own the shares. For REGN, the clearest risk is Eylea biosimilar erosion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick FDMT if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FDMT and REGN guides.

FDMT. Conventional multiples do not apply, because the revenue line is a licensing payment rather than a business. Stripping out roughly $431 million of cash and adding back $20 million of drawn Hercules debt leaves an enterprise value near $390 million on the common-share count, so the market was assigning a few hundred million dollars to a Phase 3 asset in a multi-billion-dollar indication plus four earlier programs. Book value is the only anchor with real content here, at roughly $408 million of stockholders' equity against an accumulated deficit of about $858 million, and the shares traded between roughly $5.97 and $15 over the trailing year.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.

Headline figures (approximate, August 2026): FDMT shows revenue (ttm) ~$92M, of which ~$85M was a one-time Otsuka upfront, product revenue $0, no approved products since inception, net loss (q2 2026) ~$72.9M, ~$141.7M in H1 2026, r&d expense (q2 2026) ~$68.3M, versus ~$12.5M G&A; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.

FDMT and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FDMT and REGN exposure against your real portfolio. It is not an investment adviser.